A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Steven Grant|Clinical Cancer Research|2015Cited by 48
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.Sagar Lonial, Monique C. Minnema, Marek Hus et al.|Journal of Clinical Oncology|2022Cited by 25